Family studies on the chromosomal location of the retinoblastoma gene (Rb-1)

J E N MORTEN, D G HARNDEN, AND S BUNDEY

From the Department of Cancer Studies, and Department of Clinical Genetics, University of Birmingham, Birmingham

SUMMARY  The segregation of chromosomes 13 distinguishable by Q band fluorescent polymorphisms has been studied in three families with retinoblastoma. The recombination fraction for two of these families and four families previously reported did not differ significantly from 50%. Since a high recombination fraction has been predicted from chiasma frequency between the centromere of chromosome 13 and 13q14 these results neither confirm nor refute the location of the autosomal dominant gene predisposing to retinoblastoma in 13q14. The use of fluorescent markers is not suitable for early recognition of gene carriers in families with retinoblastoma.

Predisposition to retinoblastoma can be inherited in an autosomal dominant manner with a penetrance of about 90%. This gene (Rb-1) may be acquired either by germline mutation or inheritance from a carrier parent. Of patients with retinoblastoma who have inherited the gene, 60 to 70% are bilaterally affected; on the other hand retinoblastoma patients who do not inherit the gene are invariably unilaterally affected.1,2

Twenty-six retinoblastoma patients with a constitutional chromosome 13 abnormality have been reported and there are six cases in which the abnormal D was not identified. With one exception,3 all cases where banding was done showed loss of some or all of band 13q14, and by examining banded prophase chromosomes Yunis and Ramsay4 were able to detect a sub-band deletion, del 13q(14·1:14·3), in a child with unilateral retinoblastoma.

Retinoblastoma patients with a 13q deletion are frequently bilaterally affected and it is possible that Rb-1 is located in 13q14. However, since a deletion may alter the action of genes in both the deleted and uninvolved chromosome regions one must be cautious in assigning the Rb-1 gene to 13q14. Knight et al5 have reported the segregation of Q banded chromosome 13 variants in four families with retinoblastoma and found a high frequency of discordant segregation of chromosome 13 markers and retinoblastoma.

In this report the segregation of chromosome 13 in three families with retinoblastoma has been studied.

Materials and methods

Whole venous blood was cultured in Ham’s F10 with 10% bovine serum for 48 hours. Colchicine (0·002%) was added one hour before harvesting metaphase cells.

The Q banding method was a modification of Caspersson et al.6 Slides were rehydrated and stained with quinacrine mustard (50 μg/ml) for about 30 minutes, rinsed for 5 minutes in running tap water, and mounted in McIlvaine’s buffer, pH 7·2.

The description of the markers is according to the International System for Human Cytogenetic Nomenclature (ISCN) 1978.7

Patients

The families were ascertained from index patients with bilateral retinoblastoma located by the Birmingham Regional Cancer Registry. A total of 17 live index patients was ascertained. Four families with more than one case of retinoblastoma were studied and of these three showed useful fluorescent markers of chromosome 13. Family members were studied in their own homes. Information was obtained about other relatives and the eyes of patients, parents, and sibs of patients were examined with an ophthalmoscope after pupil dilation for evidence of regressed tumours.

The pedigree of family 1 (fig 1) is part of a larger pedigree.8 The proband in family 1 (III.2) was diagnosed at 2 months of age and treated by left
Family studies on the chromosomal location of the retinoblastoma gene (Rb-1)

FIG 1 Family 1 showing Q banded chromosomes 13.

FIG 2 Family 2 showing Q banded chromosomes 13.

enucleation and irradiation and right irradiation. An osteosarcoma of the left orbit was diagnosed at 7 years of age and he died 6 months later. His mother (II.2) and aunt (II.3) did not have enucleations, but were treated by irradiation as babies. His uncle (II.4) was diagnosed at 7 months of age and was treated with irradiation and bilateral enucleation.

In family 2 (fig 2), the proband (II.3) was diagnosed at 6 months of age and treated by left enucleation; the right eye was treated with radiation starting at 6 months and enucleation was carried out at the age of 2 years. Her father (I.1) had one eye removed as a child in Poland and is assumed to have had unilateral retinoblastoma. In her brother (II.1) bilateral retinoblastomas were recognised at 12 months of age; enucleation of the left eye was performed, but it subsequently became clear that the tumour had spread beyond the orbit. The right eye was treated by irradiation, but the tumour progressed. The boy died of metastases at 9 years of age. Her sister (II.2) has a white lesion in the right retina. This was first thought to be toxoplasmosis, but since
serological tests for toxoplasma were negative and since her risk is 1 in 2 it can be assumed that she carries the retinoblastoma gene. Her left eye is clear.

The proband (III.1) of family 3 (fig 3) was diagnosed at 4\(\frac{1}{2}\) months of age and was treated by right enucleation and left irradiation. His father (II.2) developed a squint at 12 months of age and retinoblastoma was diagnosed at 2 years of age and treated by right enucleation and left irradiation. One aunt (II.3) was recognised to have bilateral retinoblastoma at 8 weeks of age and had a left enucleation at 10 weeks; the right eye was enucleated at 5 years and she died a few months later. The other aunt (II.5) had retinoblastoma of the left eye at 4 months and this eye was removed. Tumour developed in the right eye at 11 months and she died during an operation for implantation of radium seeds. Three other sibs died shortly after birth of oesophageal stricture, pneumonia, and Down's syndrome. None was recognised to have retinoblastoma. The paternal grandmother was examined and had no abnormalities of the eyes. The paternal grandfather died at the age of 37 years of tuberculosis.

Results

Family 1
Fig 1 shows the segregation of the Q banded chromosomes 13 in family 1. I.1 carries markers 13 pat 1, which has no centromeric band and has brilliant satellites, and pat 2, which has an intense band at the centromere but no fluorescent satellites. The retinoblastoma patients II.2, II.3, and II.4 show four distinguishable chromosomes 13 and though the mother with retinoblastoma is dead her markers 13 are clearly mat 1, which has no fluorescence at the centromere or satellites, and mat 2, which has an intense centromeric band and pale satellites. Though II.2, II.3, and II.4 all have retinoblastoma they do not have a marker 13 in common. If I.2 carries the Rb-1 gene on mat 1 then in generation II there is one recombinant (II.3) out of three sibs. Alternatively if the Rb-1 gene is on mat 2 there are two recombinants (II.2 and II.4) out of three sibs.

II.2 transmitted mat 1 to one child (III.4) who has not developed retinoblastoma and pat 2 to one child with retinoblastoma. Two children without retinoblastoma inherited pat 2. In generation III there are two recombinants in four sibs if Rb-1 is on 13q.

Family 2
Fig 2 shows the segregation of the Q banded chromosomes 13 in family 2.
Family studies of the chromosomal location of the retinoblastoma gene (Rb–I)

Retinoblastoma patient I.1 carries markers 13 pat 1, which has a centromeric band of medium intensity and medium fluorescent satellites, and pat 2, which has a medium fluorescent centromeric band but no fluorescent satellites. I.2 carries mat 1, which has pale satellites and no centromeric band, and mat 2, which has neither centromeric band nor fluorescent satellites.

II.2 who is probably an Rb-1 gene carrier has inherited pat 1 from I.1 and II.3 has retinoblastoma and has inherited pat 2 from I.1. Since both are probably gene carriers one must be a recombinant for chromosome 13. There is therefore one recombinant in two sibs.

FAMILY 3
Fig 3 shows the segregation of the Q banded chromosomes 13 in family 3.

II.1 carries markers 13 mat 1, which has neither centromeric band nor satellites, and mat 2, which has a pale centromeric band and satellites with almost no fluorescence.

II.2 has retinoblastoma and carries markers 13 pat 1, which has an intense fluorescent centromeric band and no fluorescent satellites, and pat 2, which has a medium fluorescent centromeric band and medium fluorescent satellites.

III.1 has retinoblastoma and carries markers 13 pat 2 and mat 1.

II.2 carries marker 13 pat 2 and a chromosome 13 with an intense fluorescent band at the centromere, medium fluorescent satellites, and a larger short arm than pat 2.

Marker pat 1 is clearly inherited from I.1 and the sister of I.1 carries two chromosomes 13 identical to pat 1.

II.8 carries chromosome 13 pat 2.

Since this family shows multiple affected sibs from unaffected parents either I.1 or I.2 is probably an unaffected Rb-1 gene carrier, but interpretation of this family is complicated by not knowing which of I.1 or I.2 is the gene carrier. If I.1 was the carrier the recombination frequency is 1/2; if I.2 carries the Rb-1 gene it is 1/3.

Recombination fraction
The recombination fraction between retinoblastoma and the fluorescent markers was calculated as a maximum likelihood estimate. For families 1 and 2 the estimate of the recombination fraction is 50%. If the four families of Knight et al9 are included in the calculation the recombination fraction estimate is 38·6% with a standard error of 15·4%, which is not significantly different from 50%.

Discussion
None of the three families with retinoblastoma showed a concordant segregation of retinoblastoma and chromosome 13. Knight et al9 found a discordant segregation in three out of four families.

Examples of families like family 3, in which there are multiple affected sibs from unaffected parents, are not uncommon (for example, 60 out of 135 families in Herrmann10). I.1 or I.2 could either be an unaffected Rb-1 gene carrier or a gonadal mosaic or, if the delayed mutation hypothesis is correct, a carrier of a premutation. Because of this uncertainty this family was not included in the calculation of the recombination fraction.

A recombination frequency between the centromere and a locus in 13q14 of 27 to 37% has been estimated from the observed chiasma frequency in normal male meiosis, and in female meiosis the recombination frequency may be nearer 50%. Thus the observed recombination frequency between retinoblastoma and the fluorescent markers of chromosome 13 which is not significantly different from 50% is compatible with, but neither confirms nor refutes, the location of Rb-1 in 13q14. Evidence that Rb-1 may not be at 13q14 has been presented by Matsunaga.11

Esterase D has been assigned to 13q1412 and Cook et al14 reported a recombination frequency between esterase D and the centromere of chromosome 13 of 44% in males and 50% in females. Studies using esterase D in families with retinoblastoma may be informative as to the location of Rb-1 in 13q14.

The high recombination frequency between retinoblastoma and the chromosome 13 fluorescent markers makes the use of fluorescent markers unsuitable for early recognition of Rb-1 gene carriers in families with retinoblastoma.

We would like to thank Dr G Gale for the calculation of the recombination fractions; Dr J A H Waterhouse of the Birmingham Regional Cancer Registry for locating bilateral retinoblastoma patients; those consultant ophthalmologists who kindly allowed us to study their patients; Susan Williams for help in preparing photographs; the Cancer Research Campaign for the grant which supported this work.

References

Requests for reprints to Dr J E N Morten, MRC Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh EH4 2XU.
Family studies on the chromosomal location of the retinoblastoma gene (Rb-1).

J Morten, D G Harnden and S Bundey

doi: 10.1136/jmg.19.2.120

Updated information and services can be found at:
http://jmg.bmj.com/content/19/2/120

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/